Neurizon Therapeutics has entered into a global licensing deal with Elanco Animal Health to advance the development of NUZ-001 for ALS.

Reflecting on a scary road rage incident reminds columnist Kristin Neva of the fragility of life. None of us is guaranteed tomorrow.

Columnist Dagmar Munn shares how she finds ways to keep her anxiety and ALS fears in check with a few simple responses.

Klotho is advancing its ALS gene therapy candidate KLTO‑202 to the manufacturing phase, and is planning the first human ...

The FDA granted orphan drug designation to Sineugene Therapeutics' SNUG01, a first-in-class experimental gene therapy for ...

As her husband's ALS journey extends, columnist Kristin Neva considers finally "settling in," so to speak, by securing a better bed.

Clene is continuing to work with U.S. regulators on its plans to seek accelerated approval of CNM-Au8 for the treatment of ...

A Q&A with author and activist Mindy Uhrlaub, who shares how she is using her voice to raise awareness and support for the ...

The Longitude Prize on ALS is offering £7.5 million to encourage scientists to use AI to speed up the search for new treatments.

The application window will close on Dec. 3, 2025, and the first set of winning teams will be announced in the first half of 2026. Research groups from the biotech, pharmaceutical, AI, and medical ...